详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China. [2]NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China. [3]Clinical Medical School, North Sichuan Medical College, Nanchong, China. [4]Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, China. [5]Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang, China [6]Pathology Department, First People's Hospital of Mianyang, Mianyang, China.

出处：

DOI：

ISSN：

关键词： CLDN6 177Lu 89Zr esophageal cancer targeted radiopharmaceutical therapy

摘要：

Advanced or metastatic esophageal cancer (EC) is associated with poor prognosis, necessitating new and effective treatment methods. We assess whether claudin 6 (CLDN6) is a useful target for the imaging and radiopharmaceutical therapy of EC using a novel pair of radioactive nuclides, 89Zr and 177Lu. Methods: CLDN6 messenger RNA expression was evaluated in 2 EC datasets (n = 436) and through a retrospective analysis of 109 patients with EC. We then used an anti-CLDN6 monoclonal antibody (IMAB027) labeled with 89Zr and 177Lu ([89Zr]Zr-DFO-IMAB027 and [177Lu]Lu-DOTA-IMAB027) for PET imaging and therapy, respectively. Imaging and biodistribution analyses were performed using the TE-1-CLDN6 xenograft model. Finally, the therapeutic potential of [177Lu]Lu-DOTA-IMAB027 was evaluated in both the TE-1-CLDN6 and the CLDN6-PDX (patient-derived xenograft) models. Results: CLDN6 messenger RNA expression was elevated in EC compared with healthy esophageal tissues. The CLDN6 expression rate was 0 in healthy esophageal tissue but was 79.8% in EC tissue. The [89Zr]Zr-DFO-IMAB027 showed the ability to effectively image EC xenografts with high CLDN6 expression. In the TE-1-CLDN6 model, there was a significant difference in tumor volume between the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 treatment group and the control group (P < 0.001). The tumor growth inhibition rate in the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 group was 101.74%. In the PDX model, significant differences in tumor volume were observed among all [177Lu]Lu-DOTA-IMAB027 treatment groups and the control group (P < 0.05). Specifically, the tumor growth inhibition rate of the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 group was 79.04%, whereas that of the 3.7-MBq group was 77.20%. However, the difference in efficacy between the high-dose and low-dose groups was not statistically significant (P > 0.05). Conclusion: The differential expression of CLDN6 between tumors and the normal esophagus shows its potential as a diagnostic and therapeutic target for EC. The radiotracer [89Zr]Zr-DFO-IMAB027 showed high contrast when visualizing CLDN6-expressing xenografts for PET imaging, and [177Lu]Lu-DOTA-IMAB027 induced rapid tumor regression in both the TE-1-CLDN6 and the CLDN6-PDX models. This research has implications for improving the radioligand diagnosis and treatment of EC.© 2025 by the Society of Nuclear Medicine and Molecular Imaging.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 1 区

医学

小类 | 1 区核医学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区核医学

第一作者：

第一作者机构： [1]Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

共同第一作者：

通讯作者：

通讯机构： [1]Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China. [2]NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China. [3]Clinical Medical School, North Sichuan Medical College, Nanchong, China. [4]Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer

文献详情

相关文献